Division of Cancer Biology, CSIR-Central Drug Research Institute (CDRI) , Lucknow, India.
Academy of Scientific and Innovative Research , New Delhi, India.
Epigenetics. 2021 Jan-Feb;16(2):144-161. doi: 10.1080/15592294.2020.1789270. Epub 2020 Jul 8.
Drug resistance is one of the trademark features of Cancer Stem Cells (CSCs). We and others have recently shown that paucity of functional death receptors (DR4/5) on the cell surface of tumour cells is one of the major reasons for drug resistance, but their involvement in the context of in CSCs is poorly understood. By harnessing CSC specific cytotoxic function of salinomycin, we discovered a critical role of epigenetic modulator EZH2 in regulating the expression of DRs in colon CSCs. Our unbiased proteome profiler array approach followed by ChIP analysis of salinomycin treated cells indicated that the expression of DRs, especially DR4 is epigenetically repressed in colon CSCs. Concurrently, EZH2 knockdown demonstrated increased expression of DR4/DR5, significant reduction of CSC phenotypes such as spheroid formation and tumorigenic potential in colon cancer. TCGA data analysis of human colon cancer clinical samples shows strong inverse correlation between EZH2 and DR4. Taken together, this study provides an insight about epigenetic regulation of DR4 in colon CSCs and advocates that drug-resistant colon cancer can be therapeutically targeted by combining TRAIL and small molecule EZH2 inhibitors.
耐药性是癌症干细胞 (CSC) 的特征之一。我们和其他人最近表明,肿瘤细胞表面功能性死亡受体 (DR4/5) 的缺乏是耐药性的主要原因之一,但它们在 CSC 中的作用知之甚少。通过利用姜黄素对 CSC 特异性的细胞毒性作用,我们发现表观遗传调节剂 EZH2 在调节结肠 CSC 中 DR 表达方面起着关键作用。我们采用无偏见的蛋白质组谱分析方法,对姜黄素处理的细胞进行 ChIP 分析,表明 DR 的表达,特别是 DR4 在结肠 CSC 中受到表观遗传抑制。同时,EZH2 敲低显示 DR4/DR5 的表达增加,结肠癌细胞球形成和致瘤潜能等 CSC 表型显著减少。对人类结肠癌临床样本的 TCGA 数据分析表明,EZH2 和 DR4 之间存在强烈的负相关。总之,这项研究提供了关于结肠 CSC 中 DR4 的表观遗传调控的见解,并主张通过联合 TRAIL 和小分子 EZH2 抑制剂可以靶向治疗耐药性结肠癌。